BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fate Therapeutics Raises $9.2 Million for Stem Cell Treatments


8/23/2012 8:27:51 AM

Fate Therapeutics Inc., a company developing stem-cell treatments, has raised $9.2 million in equity. The disclosure was made Tuesday in a regulatory filing with the Securities and Exchange Commission. Fate's technology uses chemicals called stem-cell modulators that guide the path, or "fate" of non-embryonic stem cells as they mature. Left to themselves, stem cells grow unpredictably. So methods to increase the efficiency of "reprogramming" the cells into the desired kind are much in demand. The company's most advanced treatment, ProHema, guides development of hematopoietic, or blood-forming stem cells. It's in clinical trials for blood cancer patients who are getting stem-cell transplants.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES